Infant RSV Immunity Study

Recruiting now

Conditions studied: Respiratory Synctial Virus, Asthma Childhood

In brief

Respiratory Syncytial Virus (RSV) is a main global cause of respiratory illness and death in infants. Previous infant vaccine trials have failed to demonstrate protection. Moreover, RSV infection during early infancy, particularly in infants younger than 4 months of age, is associated with more severe disease, reduced immune protection, and an increased risk of developing childhood asthma. This study aim to investigate the immunological and long-term health effects of a first exposure to RSV early (\<4 months) versus late (\>6-9 months) in infancy.

Key facts

Study ID

NCT07653347

Run by

University of British Columbia

People needed

300

Starts

2026-01-15

Expected to finish

2029-12-01

Last updated by the study team

2026-06-17

Who can join

Age: any, up to 1. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Birthing parent/child pairs with a delivery date in April, May or June or September, October or November who delivered or are planning to deliver at BC Women's Hospital + Health Centre or a nearby, local hospital.

You may not qualify if…

• Severe pregnancy-related complications or chronic medical conditions in the children making them automatically eligible to receiving RSV immunoprophylaxis in British Columbia (e.g. infants born prematurely < 35 weeks of gestation, or with chronic medical conditions).

Where it is running

• BC Women's Hospital and Health Centre — Vancouver, British Columbia, Canada (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.